LIF and MDM2 Inhibiting Cytotoxic Compounds for Chemoresistance
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current cancer treatments face challenges in effectively targeting cancer stem cells and carcinoma-associated fibroblasts, leading to chemoresistance and poor prognosis, due to the role of leukemia inhibitory factor (LIF) in promoting tumorigenesis and drug resistance, with limited small molecule inhibitors available.
Innovation Solution
Development of cytotoxic compounds that simultaneously inhibit LIF and MDM2, targeting both tumor cells and stromal fibroblasts to downregulate STAT3 phosphorylation and stabilize p53 levels, thereby overcoming chemoresistance.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If conventional chemotherapeutic agents are administered at maximum tolerated dose, then tumor cell elimination is improved, but bone marrow depression and immunosuppression worsen
Solution Approach 1:
The patent applies local quality by designing compounds with specific structural features (steroid nucleus with particular substituent patterns at positions 11, 17, and 21) that confer selective toxicity toward cancer cells while sparing normal bone marrow cells. The compounds exhibit differential interaction with LIF receptors in tumor versus normal cells, achieving localized therapeutic effect.
Solution Approach 2:
The patent employs parameter changes by optimizing specific molecular parameters of the chemotherapeutic compounds, including the nature of substituents (R1-R6 groups), their positions, and stereochemistry. These parameter optimizations enable the compounds to achieve enhanced tumor selectivity and reduced bone marrow toxicity compared to conventional agents.
2Reliability
If targeted therapies are used to increase selectivity, then treatment efficacy is improved, but the availability of effective small molecule inhibitors targeting LIF worsens
Solution Approach 1:
The patent applies universality by creating small molecule compounds that can target multiple aspects of cancer pathogenesis simultaneously. The compounds inhibit LIF signaling pathways while also affecting related cytokine receptors, providing multi-functional therapeutic activity that overcomes the limitation of scarce LIF-specific inhibitors.
Solution Approach 2:
The patent employs composite materials by combining steroid structural motifs with specific functional groups to create hybrid molecules that possess both high affinity for LIF receptors and favorable pharmacokinetic properties. This composite molecular design enables the compounds to function as effective small molecule inhibitors where none previously existed.
3Reliability
If cancer stem cells are targeted, then chemoresistance is reduced, but the ability to effectively eliminate these cells worsens
Solution Approach 1:
The patent applies preliminary action by designing compounds that preemptively target LIF signaling pathways known to be critical for cancer stem cell maintenance and survival. The compounds interfere with these protective pathways before chemoresistance can fully develop, making cancer stem cells vulnerable to elimination.
Solution Approach 2:
The patent employs intermediary mechanisms by utilizing LIF as a mediator of cancer stem cell survival. The compounds block LIF signaling, which acts as an intermediary between the tumor microenvironment and cancer stem cells, thereby eliminating the protective effect and enabling effective cell death.
4Reliability
If LIF signaling is inhibited, then tumor growth is reduced, but the mechanism of action differs from conventional therapies
Solution Approach 1:
The patent applies taking out by isolating and targeting the specific LIF signaling pathway as a distinct therapeutic intervention. The compounds selectively inhibit LIF receptor signaling while leaving other cancer-related pathways intact, providing a focused mechanism of action that differs from the broad-spectrum approach of conventional therapies.
Data Source
Figure 1
Figure 2
Figure 3~4A
AI summary
Described herein are new anti-cancer compounds and methods of using such compounds, acting through a new mechanism of action by simultaneous inhibition of leukemia inhibitory factor (LIF) and MDM2. In one embodiment, a cytotoxic compound has the structure (I) or (II). In an embodiment, a method of treating cancer in a subject comprising administering to a subject a medicament comprising an effective amount of a cytotoxic small molecule compound that inhibits leukemia inhibitory factor or leukemia inhibitory factor receptor.